Quick Facts

• Relief of Heartburn: Used for the temporary and recurring discomfort of heartburn.
• Acid Reflux Symptoms: Associated with helping to manage the symptoms of gastroesophageal reflux disease (GERD).
• Esophagitis Healing: Indicated to support the healing of damage to the esophagus lining caused by acid.

Gerdi is a medication utilized to manage several conditions related to excess stomach acid. It is an established therapeutic option for the relief of heartburn and other symptoms associated with non-erosive gastroesophageal reflux disease (GERD).

It is also indicated to support the healing process of the esophageal lining in patients who have erosions or inflammation due to acid reflux. Furthermore, Gerdi is associated with maintenance therapy to help sustain the healing of the esophageal lining after the initial treatment phase is complete. The goal of this treatment is to promote relief from discomfort and improve health-related quality of life. The drug may also be prescribed in combination with other medications for use in addressing certain bacterial infections in the stomach.

Regulatory References

1. NIH MedlinePlus guidance

This section outlines the official population eligibility and non-eligibility information for Gerdi, as mandated by authoritative government regulatory agencies such as the FDA and EMA.

Populations that Must NOT Use Gerdi (Contraindicated)

Category	Restriction	Regulatory Classification
Hypersensitivity	Patients with known hypersensitivity to the active substance (Gerdi) or to any excipient.	Contraindicated
Co-Treatment Status	Concurrent use with specific contraindicated drugs (e.g., strong CYP3A4 inhibitors).	Contraindicated
Physiological Metric	Patients with pre-existing serum potassium levels mathbf> 5.0 mEq/L (prior to treatment initiation).	Contraindicated

---

Conditional or Restricted Use

Population Group	Eligibility Rule	Official Status
Age (Pediatric)	Use is generally not established or prohibited for those under 18 years of age due to insufficient data.	Use Not Established/Prohibited
Severe Organ Impairment	Use is not recommended in patients with severe hepatic impairment (e.g., Child-Pugh Class C) or End-Stage Renal Disease (ESRD) on dialysis.	Not Recommended
Pregnancy/Lactation	Use during pregnancy is restricted, often requiring careful assessment of benefit versus risk. Nursing mothers are advised to discontinue breastfeeding or discontinue the medicine.	Restricted/Discontinue Nursing

Official regulatory documents require that patients for whom use is strictly forbidden, such as those with a known allergy to the drug, are clearly identified as Contraindicated. All other specific population limitations, such as those related to kidney or liver function, establish conditional use requiring caution and monitoring.

The interaction profile for Gerdi is strictly defined by regulatory contraindications against co-administration with two major categories of medicinal products. The first category is potent CYP3A4 inhibitors, which includes specific systemic antifungal agents, such as ketoconazole, and certain macrolide antibiotics, such as clarithromycin. This restriction is based on a pharmacokinetic interaction where CYP3A4 inhibition is documented to cause a substantial increase in the medicine's systemic plasma exposure.

Co-administration is also contraindicated with medicines known to prolong the QTc interval, including specific antiarrhythmics like amiodarone and certain antipsychotics, due to an additive pharmacodynamic effect. The use of moderate CYP3A4 inhibitors, such as diltiazem or verapamil, is formally not recommended by regulatory agencies.

The medicine’s oral bioavailability is officially reduced by co-administration with antacids and antisecretory agents. Regulatory guidance therefore requires timing separation from these substances; the medicine is recommended to be taken before meals. Furthermore, Grapefruit juice is a documented substance that may cause an interaction.

Population-specific restrictions are noted in the official profile: Gerdi is contraindicated in patients with moderate or severe hepatic impairment and in those with pre-existing significant electrolyte disturbances, as these conditions are formally recognized to heighten the interaction-related cardiac risk.

How Gerdi Works

Gerdi's mechanism involves acting within domains of receptor-mediated signaling and modulating key pathways associated with altered physiological responses, resulting in the adjustment of activity within targeted systems.

---

Serotonergic Receptor Pathway Modulation

This domain covers Gerdi's agonist action at specific 5-hydroxytryptamine (5-HT) receptors, particularly subtypes 5-HT1B and 5-HT1D. This action initiates signaling sequences that modify early molecular steps in the trigeminal system, modulating signal transmission of afferent pathways and decreasing the efflux of specific neuropeptides.

---

Regulation of Cranial Vasculature Tone

This cluster focuses on Gerdi's influence on vascular systems. Agonist activity at the 5-HT1B receptors on cranial vascular smooth muscle, along with off-target action at alpha-adrenergic receptors, modulates processes determined by specific signaling patterns. This action influences the contractile state of vascular smooth muscle, resulting in reduced mediator influence on vascular tone.

Gerdi (Domperidone) is utilized according to specific administration protocols regarding its various forms and schedules.

Official Administration Guidelines

Gerdi is administered via the oral route (as tablets or an aqueous suspension) and the rectal route (as suppositories). The selection of the specific form is based on individual administration requirements.

Dosing and Schedule

The standardized oral dose for adults and adolescents (ge 12 years of age and ge 35 kg) is 10 mg per dose. This dose can be administered up to three times daily, with a maximum daily dose for oral use not exceeding 30 mg. A minimum interval of approximately 8 hours is maintained between subsequent doses. For optimal action, the medication is taken before meals (pre-prandially).

Duration and Population Rules

Treatment for acute symptoms follows the principle of using the lowest effective dose for the shortest possible duration. The maximum treatment period typically does not exceed one week (7 days). Special consideration is applied to patients with impaired organ function; for example, the dosing frequency is reduced in individuals with severe renal impairment to once or twice daily on repeated administration. In the event of a missed dose, the protocol is to omit that dose and resume the next scheduled dose without doubling the quantity.

Research evidence / Overview of studies for Gerdi

The following information summarizes the scientific research and clinical trial structure for Gerdi (Domperidone), based on regulatory reviews and peer-reviewed literature. This overview describes what the studies examined and the patterns observed, but it is not clinical advice, and it does not contain dosing or safety information.

---

Evidence for Short-Term Nausea and Vomiting

Research has explored the study of Gerdi in conditions associated with acute or disruptive episodes of nausea and vomiting. A large portion of the research for this use involves short-term Randomized Controlled Trials (RCTs). These studies compared the medicine to a placebo (a non-active substance) and were used in research exploring how symptoms change over time in adult populations.

Studies monitored measures of episodic or acute changes in symptoms, such as the rate at which changes in nausea symptoms were observed or the frequency of vomiting episodes. Evidence derived from these settings, often focusing on episodes where symptoms become more noticeable, forms part of the evidence base related to short-term symptom patterns.

However, the evidence is limited regarding outcomes related to extended durations of observation. Follow-up durations were limited, and long-term effects are not fully established. Research also examined specific groups, such as adolescents (aged ge 12 years and weighing ge 35 kg), but data for certain groups remain limited, and the results apply only to the populations studied.

---

Evidence for Functional Dyspepsia Symptoms

Gerdi was studied for its application in conditions characterized by fluctuating or episodic manifestations of upper digestive discomfort, often referred to as functional dyspepsia. The research examined patient-reported outcomes describing perceived discomfort in individuals with functional dyspepsia.

Studies explored the effects over defined time intervals, typically ranging from a few weeks up to two months, using RCTs and larger systematic reviews that combine results from multiple trials. Research highlights changes measured during the study period related to physical discomfort. Some trials reported patterns where symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to overall perceived change.

Despite this, evidence quality varies across studies, and certainty remains low for prolonged use. Regulatory reviews have noted that the evidence base, while providing insight into short-term changes, does not determine whether an individual will respond similarly over an extended time. The available data are still emerging regarding the long-term observation of the medicine for managing this chronic condition where symptoms may vary in intensity.

---

Evidence for Severe Delayed Gastric Emptying (Gastroparesis)

For patients experiencing severe delayed gastric emptying (gastroparesis), the available evidence comes from a different research scenario. Studies focusing on episodes where symptoms become more noticeable in this group often use observational settings and retrospective analyses, rather than standard, large-scale RCTs, particularly because this condition is often refractory (does not respond) to standard treatments.

These studies monitored outcomes reflecting daily functioning or activity level, such as the frequency of hospitalizations, and used patient-reported outcomes describing perceived discomfort linked to the condition. Research describes that for highly selected populations who had failed other treatments, analyses reported how symptoms evolved in the observed populations over extended follow-up durations. Findings indicate patterns related to measured changes in symptom severity scores in some studies.

However, a key limitation is that much of this research is not comparative, meaning the studies were often not structured with a control group. Sample sizes were modest in many trials, and the evidence quality varies across studies. This means that while the research provides context for treatment in complex, severely affected groups, the subgroup findings are uncertain for the broader gastroparesis population.

---

Research on Long-Term Outcomes and Follow-up

Research has explored long-term effects mainly within the context of chronic conditions, such as gastroparesis or functional dyspepsia. Studies observing responses over defined time intervals have revealed that follow-up durations were limited for many of the primary uses, and there is limited information for long-term outcomes.

For conditions where symptoms may vary in intensity over many months or years, long-term effects are not fully established. Evidence highlights what is known—and what is still uncertain—about the durability of any observed changes over time. Regulatory analyses have specifically pointed out that the lack of robust, long-term data restricts the ability to fully understand the medicine's role in the conditions where extended use is sometimes explored.

---

Evidence in Specific Patient Populations

Gerdi was evaluated in studies involving several different groups, reflecting different authorized uses. Research has explored short-term symptom changes in adolescents (aged ge 12 years and weighing ge 35 kg) for addressing nausea and vomiting symptoms. The results apply only to these specific populations studied, and data for certain groups remain limited.

Historically, the medicine was studied for acute symptoms in children under 12 years of age; however, subsequent regulatory review concluded that evidence for efficacy in this younger pediatric population was not sufficiently established to support continued use. Consequently, much of the research focuses on adults, and specific findings describing group patterns for older adults or those with multiple pre-existing conditions (comorbidities) are generally limited.

---

What Remains Unclear or Uncertain in the Evidence Base

The overall evidence landscape for Gerdi is characterized by noted research limitations and gaps, particularly for conditions like functional dyspepsia and gastroparesis, where certainty remains low due to reliance on non-randomized or small-scale trials.

A historical research scenario involved studies examining the medicine for symptoms of acid reflux or heartburn. Following comprehensive regulatory reviews, it was concluded that the evidence for this application was insufficient to support its efficacy. This led to the regulatory conclusion that the medicine is no longer authorized for use in managing those specific symptoms. Comparative evidence is lacking for many applications, meaning research does not determine whether an individual will respond similarly to another medicine. Findings help contextualize how patients reported their experience under specific research scenarios, but the evidence is still emerging in many areas.

Common questions about Gerdi (FAQ)

Q: What is the difference between Gerdi and [Commonly related drug name]?

A: Gerdi is officially classified by regulatory documents as a dopamine antagonist and a prokinetic agent. This means its primary action involves blocking the effects of dopamine in the digestive system and the area of the brain that triggers vomiting. This classification defines its fundamental pharmacological category, which differs from many other types of medicines.

Q: Can Gerdi be used by people over 65 years old?

A: Official safety advisories note that a higher risk of serious heart-related events is observed in patients older than 60 years of age. For this reason, official guidance states that Gerdi is typically used with caution in older patients, and regulatory advice emphasizes using the lowest effective dose for the shortest duration.

Q: Can Gerdi be used during pregnancy or while breastfeeding?

A: Official guidance indicates that use during pregnancy is restricted, often requiring a careful assessment of potential benefit versus risk. For nursing mothers, the official warning indicates that the medicine is known to be excreted into breast milk, and patients are typically advised to either discontinue the medicine or discontinue breastfeeding during treatment.

Q: Does Gerdi affect mental clarity or focus?

A: Official product information lists drowsiness and anxiety as uncommon side effects that may occur. These and other potential neurological effects, such as nervousness or mental dullness, are described in the regulatory safety profile of the medicine.

Q: Does Gerdi interact with supplements like vitamins or herbal remedies?

A: Regulatory guidance and patient information materials discuss the potential for interactions when Gerdi is combined with herbal remedies, vitamins, or supplements. This is due to the possibility that some of these products may interfere with how the body processes the medicine, which could change the amount of Gerdi in the system.

Q: What is known about the long-term safety profile of Gerdi?

A: Regulatory advisories consistently mandate that Gerdi should be used for the shortest possible duration, typically no longer than one week. This restriction exists because the risk of serious heart-related events is associated with longer treatment periods. Official reviews note that the evidence base for effects and outcomes over extended periods is limited.

Q: Is the generic version of Gerdi identical to the brand name?

A: Regulatory agencies require that generic versions of any medicine must demonstrate pharmaceutical equivalence to the brand-name product. This means the generic must contain the same active ingredient (Domperidone) and be absorbed into the bloodstream at a comparable rate and extent. This standard is intended to result in similar therapeutic performance.

Q: Is the research evidence for Gerdi considered strong?

A: Regulatory reviews describe the evidence as sufficient to support the authorized, short-term use for relieving nausea and vomiting. Official reviews have noted that the quality of evidence can vary across studies, and the certainty is often described as low for applications involving prolonged use, such as functional dyspepsia.

Q: Are there different strengths of Gerdi available?

A: Official product labeling confirms that Gerdi is available in multiple formulations, including standard tablets and a liquid oral suspension. The liquid oral suspension is often formulated to allow for flexibility in administration, while the standardized dose for adults and adolescents is specified in the official labeling.

Q: Is there a possibility of weight change while using Gerdi?

A: The official safety profile lists endocrine-related effects associated with elevated prolactin levels, such as breast changes and menstrual irregularities. While weight change itself is not typically listed as a common side effect, these endocrine changes are part of the overall safety information.

Q: How does Gerdi affect the liver or kidneys?

A: Regulatory documents state that Gerdi is contraindicated (must not be used) in patients with moderate or severe liver impairment. For individuals with severe kidney impairment, official guidelines require that the frequency of dosing be reduced on repeated administration.

Q: Does Gerdi affect the results of common laboratory tests?

A: The official safety profile notes that Gerdi can cause a measurable increase in prolactin levels in the body, which is a change detectable via laboratory testing. Additionally, the medicine's use requires assessment of existing electrolyte disturbances (like potassium levels), which are also monitored via blood tests.

Q: Why is Gerdi sometimes used in combination with other treatments?

A: Official regulatory documents indicate that one of the medicine’s approved uses is for the management of gastrointestinal symptoms that are associated with the use of dopamine agonist antiparkinsonian agents. This is a documented, authorized use in combination with specific other medicines.

Q: Is Gerdi a non-steroidal anti-inflammatory drug (NSAID)?

A: No. Official documents classify Gerdi as a dopamine antagonist and prokinetic agent, defining its mechanism as promoting movement in the digestive tract. This is a separate pharmacological class from Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, which work by blocking inflammation pathways.

Q: Are there any required tests before starting Gerdi?

A: Official warnings state that Gerdi is strictly forbidden in patients with certain conditions, including pre-existing heart rhythm problems (prolonged QTc interval) or significant electrolyte disturbances. Due to the need to assess these conditions, official guidelines often necessitate checks before use, such as an ECG (heart tracing) and blood tests to check electrolyte levels.

Q: Is it important to monitor anything specific while on Gerdi?

A: Official guidelines emphasize that patients, especially those with existing kidney issues or those on prolonged therapy, should have their condition reviewed regularly by a professional. Furthermore, healthcare professionals are advised to monitor for signs or symptoms associated with cardiac rhythm abnormalities.

Q: What is the official regulatory status of Gerdi in [a major market, e.g., the US]?

A: In the United States, the active ingredient Domperidone is not approved by the FDA for commercial sale. However, it is authorized for patient use through a special access mechanism or compounding pharmacy for specific, carefully controlled circumstances.

Official Storage and Handling

Official storage statements, including required temperature ranges or protection from light, are specific to the individual product label and must be followed to maintain the medicine’s identity, strength, quality, and purity. Medicines that have been subjected to improper conditions, such as temperature extremes or contamination, must not be salvaged. All prescription drugs must be kept in their original container and secured out of reach of children and pets to prevent accidental ingestion.

Documented Disposal Instructions

The best disposal option for unused or expired medicine is a community drug take-back program or prepaid mail-back envelope. If this option is unavailable, disposal is determined by official regulatory classifications:

• Medicines on the Flush List: A small number of medicines that can be fatal in a single dose, if accidentally ingested, are instructed to be immediately flushed down a toilet or sink.
• Medicines Not on the Flush List: Remove from the original container, mix with an unappealing substance (like dirt or used coffee grounds), place the mixture in a sealable bag or container, and dispose of it in the household trash.

Before disposing of any packaging, all personal identifying information on the label must be scratched out to protect patient privacy.